Russell Swerdlow
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
While both Primary Age-Related Tauopathy (PART) and Alzheimer’s Disease (AD) involve the accumulation of hyperphosphorylated tau (pTau)-positive neurofibrillary tangles (NFTs) in the hippocampus, PART is distinguished by the absence of β-amyloid (Aβ) deposition and is generally associated with milder cognitive impairment than AD. To delineate cellular and molecular mechanisms that are common or uniquely linked to disease progression in PART and AD, we constructed a transcriptome-wide, high-resolution atlas of the human hippocampus using samples from six individuals spanning the aged control (AC), PART, and AD groups. Our results supported that PART represent a precursor stage of AD, as evidenced by the altered transcriptional profiles of excitatory neurons (Exc) in the PART group, which exhibited a markedly increased capacity to promote Aβ production compared to both AC and AD groups. While the microglia (Mic) were reactivated in the PART group, this response was reduced in AD samples despite the presence of Aβ deposition, and appeared to further induce NFTs formation as a loop consequently driving the progression from PART to AD. Furthermore, subregion interactions in the signalling pathways related to neuronal survival and the maintenance of blood-brain-barrier (BBB) integrity were decreasing in the PART and disrupted in the AD groups, compared to the AC group. Additionally, we found a P53 signalling-related gene, TP53INP2 , was uniquely upregulated in astrocytes near large vessels in AD. This suggests a potential mechanism of vessel-induced neuronal apoptosis in AD, a feature absent in AC and PART. In summary, our study offers new insights into the relationship between PART and AD, along with the molecular mechanisms driving the transition from PART to AD. Furthermore, we identified key molecular pathways associated with BBB disruption and vascular-associated neuronal degradation in AD which were absent in PART. These findings deepen our understanding of AD pathogenesis and may inform the development of targeted therapeutic strategies.
Year:
2025
APOE ε4 is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD), but its contribution to disease pathogenesis remains incompletely understood. Here, we integrate proteomic profiling of plasma, cerebrospinal fluid (CSF), and brain tissue from over 10,000 individuals to define the immune phenotype associated with APOE ε4. We identify a conserved, allele dose-dependent pro-inflammatory immune signature across peripheral and central tissues independent of AD diagnosis. This signature is enriched in adaptive immune cells and white matter-resident glial and vascular cells. It also emerges in patient-derived cortical organoids prior to amyloid-β and tau pathology, supporting a causal, genotype-driven mechanism. Cross-tissue comparisons reveal shared innate and antiviral responses alongside tissue-specific immune signaling. Notably, a 12-week medical ketogenic diet partially reversed the APOE ε4 immune signature. These findings position immune dysregulation as an early and tractable driver of AD risk in APOE ε4 carriers with direct implications for targeted prevention strategies.
Year:
2025
Collaborators (7)
Caitlin Finney
Translational Dementia Research Group Leader
Westmead Institute for Medical Research
Mohammad Haeri
Assistant Professor
University of Kansas Medical Center
Jeffrey Burns
University of Kansas Medical Center
Hongwen Deng
Founding Director
Tulane University School of Medicine
Ann-Na Cho
Senior Lecturer (Tenure)
University of Sydney
Hui Shen
Associate Professor
Tulane University
Farhad Imam
Assistant Professor
University of California, San Diego
Make your next move.
Prepare your application
Review drafts before you send them.